While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats

While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats

Source: 
Endpoints
snippet: 

While Novartis is battling to weaken the challengers vying to market copycat versions of its blockbuster multiple sclerosis treatment Gilenya — the US drug regulator on Thursday approved a trifecta of the drug’s first knockoffs. When they will launch is another question altogether.